Clinical efficacy of first-line immunotherapy plus anti-angiogenesis targeted therapy in the treatment of advanced hepatocellular carcinoma
10.3760/cma.j.cn115610-20210628-00316
- VernacularTitle:免疫联合抗血管生成靶向一线治疗晚期肝癌的临床疗效
- Author:
Xiuju LIANG
1
;
Xiao LIU
;
Guili ZHENG
;
Min DONG
;
Baocheng WANG
;
Shifeng XU
;
Chen ZHONG
Author Information
1. 中国人民解放军联勤保障部队第960医院肿瘤科，济南 250031
- Keywords:
Liver neoplasm;
Advanced;
Immunotherapy;
Targeted therapy;
Patho-logic complete response;
Case analysis;
Clinical efficacy
- From:
Chinese Journal of Digestive Surgery
2021;20(S2):15-19
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma has a high morbidity and mortality, which has seriously harmed human health. Several targeted therapies have been approved for the first- and second-line treatment of advanced hepatocellular carcinoma. The emergence of immunotherapy has brought the treatment of hepatocellular carcinoma into a new era. Targeted and immunotherapeutic agents have synergistic effects in mechanism, also the combination of these two therapies has been clinically beneficial to patients with advanced hepatocellular carcinoma. At the same time, in addition to the systemic therapy of targeted combined immunological, applying appropriate local therapy can provide a longer survival period or even a chance of cure for that some patients. The authors introduce the diagnosis and treatment of a case of advanced hepatocellular carcinoma who achieved pathological complete remission by first-line immunotherapy combined with anti-angiogenesis targeted therapy.
